MCD
MCID: MLT113
MIFTS: 48

Multicentric Castleman Disease (MCD)

Categories: Blood diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Multicentric Castleman Disease

MalaCards integrated aliases for Multicentric Castleman Disease:

Name: Multicentric Castleman Disease 11 19 14
Plasmablastic Multicentric Castleman Disease 11 19
Multicentric Giant Lymph Node Hyperplasia 11 19
Idiopathic Multicentric Castleman Disease 58 75
Multi-Centric Castleman's Disease 43 71
Pmcd 11 19
Mcd 11 19
Human Herpesvirus-8-Negative Multicentric Castleman Disease 58
Multicentric Plasma Cell Variant of Castleman's Disease 19
Hhv-8-Negative Multicentric Castleman Disease 58
Idiopathic Multicentric Castleman's Disease 19

Characteristics:


Prevelance:

Idiopathic Multicentric Castleman Disease: 1-9/1000000 (United States) 58

Age Of Onset:

Idiopathic Multicentric Castleman Disease: All ages 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0111152
MeSH 43 C537372
NCIt 49 C27855
SNOMED-CT 68 1156805003
ICD10 via Orphanet 32 D47.7
Orphanet 58 ORPHA570431
UMLS 71 C1334815

Summaries for Multicentric Castleman Disease

GARD: 19 "Multicentric Castleman Disease (MCD) is a rare disease that affects the lymph nodes and related tissues. It is a form of Castleman disease that is ""systemic"" and involves multiple regions of lymph nodes (as opposed to unicentric Castleman disease, which involves a single lymph node or single region of lymph nodes). The signs and symptoms of MCD are often nonspecific, and are mild in some people but serious in others. Symptoms may include enlarged lymph nodes in multiple regions, fever, weight loss, nausea, rash, and/or an enlarged large liver and spleen. The disease is diagnosed based on the symptoms present, laboratory test results, imaging studies, and results of a biopsy of the lymph nodes which shows specific features when studied under the microscope. In some cases, MCD is caused by human herpesvirus-8 (HHV-8) and is referred to as HHV-8-associated MCD. In other cases, the cause is not known and it is referred to as HHV-8 negative MCD, or idiopathic MCD (iMCD)."

MalaCards based summary: Multicentric Castleman Disease, also known as plasmablastic multicentric castleman disease, is related to kaposi sarcoma and polyclonal hypergammaglobulinemia, and has symptoms including fever An important gene associated with Multicentric Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Thalidomide and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include lymph node, spleen and liver, and related phenotypes are homeostasis/metabolism and neoplasm

Disease Ontology: 11 A Castleman disease characterized by systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6.

Wikipedia: 75 Idiopathic multicentric Castleman disease (iMCD) is a subtype of Castleman disease (also known as giant... more...

Related Diseases for Multicentric Castleman Disease

Diseases related to Multicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 860)
# Related Disease Score Top Affiliating Genes
1 kaposi sarcoma 32.0 VEGFA SDC1 IL6R IL6 H2AC18
2 polyclonal hypergammaglobulinemia 31.1 IL6 CRP CD4 CCR6
3 poems syndrome 31.0 VEGFA MYOM2 IL6
4 lymphoproliferative syndrome 30.7 TNFRSF8 IL10 CCR6 BCL6 ALK
5 membranoproliferative glomerulonephritis 30.7 CRP CFHR2 CD79A
6 glomerulonephritis 30.6 IL6 IL10 CRP CD79A
7 vasculitis 30.6 IL6 IL10 CRP CD79A
8 autoimmune disease 30.5 IL6 IL10 CRP CD79A CCR6
9 brucellosis 30.5 IL6 IL10 CRP
10 glomeruloid hemangioma 30.5 VEGFA MYOM2
11 juvenile rheumatoid arthritis 30.5 IL6 CRP CD4 CCR6
12 nephrotic syndrome 30.4 VEGFA IL6 CRP CD79A CD4
13 mesangial proliferative glomerulonephritis 30.4 IL6 CFHR2 CD79A
14 dacryoadenitis 30.4 IL10 CD4 CCR6
15 adult-onset still's disease 30.4 IL6 CRP CCR6
16 familial mediterranean fever 30.4 IL6 IL10 CRP
17 nonspecific interstitial pneumonia 30.4 CRP CD4 CCR6
18 aplastic anemia 30.4 IL6 IL10 H2AC18 CD4 CCR6
19 castleman disease 30.3 VEGFA TNFRSF8 SDC1 MYOM2 IL6R IL6
20 pancytopenia 30.3 IL6 H2AC18 CRP CD4 CD19
21 lymphoid interstitial pneumonia 30.3 IL6 CRP CD4 CD19
22 lung disease 30.3 VEGFA IL6 IL10 H2AC18 CCR6
23 erysipelas 30.3 MYOM2 IL6 CRP
24 interstitial lung disease 30.2 IL6 IL10 H2AC18 CRP CCR6
25 syphilis 30.2 CRP CD79A CD4 CCR6
26 igg4-related disease 30.2 SDC1 IL10 CRP CD4 CD38 CD19
27 purpura 30.2 IL6 IL10 CRP CD79A
28 herpes zoster 30.2 IL10 CD4 CCR6
29 osteosclerotic myeloma 30.2 VEGFA MYOM2 IL6
30 aseptic meningitis 30.2 IL6 IL10 CRP CD4
31 papilledema 30.2 VEGFA MYOM2 IL6 CRP CD4
32 thrombocytopenia 30.2 VEGFA PAX5 IRF4 IL6 IL10 CRP
33 mikulicz disease 30.1 IL10 CRP CD4 CCR6
34 urticaria 30.1 IL6 IL10 CRP CD4
35 collagen disease 30.1 IL6 H2AC18 CRP CFHR2 CCR6
36 proliferative glomerulonephritis 30.1 MYOM2 H2AC18 CFHR2 CD79A CCR6
37 meningitis 30.1 VEGFA IL6 IL10 CRP
38 agammaglobulinemia, x-linked 30.1 CD79A CD19 CCR6
39 synovitis 30.1 VEGFA IL6 IL10 CRP
40 anemia, autoimmune hemolytic 30.0 IL6 IL10 CRP CD4 CD38 CD19
41 acquired immunodeficiency syndrome 30.0 IL6 IL10 CRP CD79A CD4 CD38
42 bacterial sepsis 30.0 IL6 IL10 CRP CD4 CCR6
43 evans' syndrome 30.0 CD4 CD38 CD19 CCR6
44 viral infectious disease 30.0 IL6 IL10 H2AC18 CD4 CCR6
45 cellulitis 29.9 MYOM2 IL6 CRP CD4 CCR6
46 agammaglobulinemia 29.9 IRF4 IL6 CD79A CD19
47 b-cell lymphoma 29.9 TNFRSF8 PAX5 IRF4 BCL6 ALK
48 histiocytosis 29.9 TNFRSF8 CCR6 ALK
49 inherited metabolic disorder 29.9 IL6 H2AC18 CRP CCR6
50 thrombocytopenia due to platelet alloimmunization 29.9 IL10 CD4 CD19 CCR6

Graphical network of the top 20 diseases related to Multicentric Castleman Disease:



Diseases related to Multicentric Castleman Disease

Symptoms & Phenotypes for Multicentric Castleman Disease

UMLS symptoms related to Multicentric Castleman Disease:


fever

GenomeRNAi Phenotypes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ALK BCL6 CCR6 CD19 CD38 CD4
2 no effect GR00402-S-2 10.18 ALK BCL6 CCR6 CD19 CD38 CD4

MGI Mouse Phenotypes related to Multicentric Castleman Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ALK BCL6 CCR6 CD19 CD38 CD4
2 neoplasm MP:0002006 10.13 ALK CD19 CD79A IL10 IL6 IL6R
3 normal MP:0002873 10.06 ALK BCL6 CCR6 CD19 CD79A IL10
4 endocrine/exocrine gland MP:0005379 10 ALK BCL6 CD38 CD4 IL10 IL6
5 liver/biliary system MP:0005370 9.97 BCL6 CD19 CD79A HAMP IL10 IL6
6 cellular MP:0005384 9.93 BCL6 CD19 CD38 CD4 CD79A IL10
7 immune system MP:0005387 9.86 BCL6 CCR6 CD19 CD38 CD4 CD79A
8 hematopoietic system MP:0005397 9.5 BCL6 CCR6 CD19 CD38 CD4 CD79A

Drugs & Therapeutics for Multicentric Castleman Disease

Drugs for Multicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
2
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
3
Zidovudine Approved Phase 2 30516-87-1 35370
4
Zanubrutinib Approved, Investigational Phase 2 1691249-45-2 135565884
5
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
6
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
7
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
9
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
11
Siltuximab Approved, Investigational Phase 2 541502-14-1
12 Anti-Retroviral Agents Phase 2
13 Antimetabolites Phase 2
14 Antiviral Agents Phase 2
15 Anti-HIV Agents Phase 2
16 Reverse Transcriptase Inhibitors Phase 2
17 Anti-Infective Agents Phase 2
18 Chrysarobin Phase 2
19 Immunoglobulins, Intravenous Phase 2
20 Protein Kinase Inhibitors Phase 2
21 Antifungal Agents Phase 2
22 Immunoglobulins Phase 2
23 Antibodies, Monoclonal Phase 2
24 Antibodies Phase 2
25
Picropodophyllin Approved, Investigational Phase 1 518-28-5, 477-47-4 10607 72435
26
Levoleucovorin Approved, Experimental, Investigational Phase 1 68538-85-2, 58-05-9, 73951-54-9 149436 6006
27
Methotrexate Approved Phase 1 1959-05-2, 59-05-2 4112 126941
28
Daunorubicin Approved Phase 1 20830-81-3 30323
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
30 Folic Acid Antagonists Phase 1
31 Folate Phase 1
32 Vitamin B9 Phase 1
33 Keratolytic Agents Phase 1
34 Vitamin B Complex Phase 1
35 Dermatologic Agents Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Unknown status NCT03043105 Phase 2 Thalidomide, cyclophosphamide and prednisone
2 Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease Completed NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
3 LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial Recruiting NCT04585893 Phase 2 Rituximab;Etoposide
4 The Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castleman Disease (iMCD): a Prospective, Single-center, Single-arm Trial Recruiting NCT04743687 Phase 2 Zanubrutinib
5 A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease Recruiting NCT03933904 Phase 2 Sirolimus
6 A Single-arm, Open-label, Multi-center Phase Ⅱa Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-IL-6R mAb Injection in the Treatment of Patients With Idiopathic Multicentric Castleman's Disease Recruiting NCT05345522 Phase 2
7 Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03982771 Phase 2 Bortezomib;Cyclophosphamide;Dexamethason
8 A Phase 2 Study of Intrapatient Siltuximab Dose Escalation in Patients With Idiopathic Multicentric Castleman Disease That Has Progressed After Prior Siltuximab Treatment Terminated NCT04838860 Phase 2 Siltuximab
9 Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB) Terminated NCT00127569 Phase 2 Rituximab
10 Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
11 A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda Recruiting NCT03864419 Phase 1 Cyclophosphamide;Vincristine;Methotrexate;Doxorubicin;Doxorubicin Hydrochloride;Prednisone;Etoposide
12 Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis Active, not recruiting NCT04742387

Search NIH Clinical Center for Multicentric Castleman Disease

Cochrane evidence based reviews: multi-centric castleman's disease

Genetic Tests for Multicentric Castleman Disease

Anatomical Context for Multicentric Castleman Disease

Organs/tissues related to Multicentric Castleman Disease:

MalaCards : Lymph Node, Spleen, Liver, Bone, Bone Marrow, B Cells, Lung

Publications for Multicentric Castleman Disease

Articles related to Multicentric Castleman Disease:

(show top 50) (show all 691)
# Title Authors PMID Year
1
Deconstructing the liquid architecture of human herpesvirus 8 diseases. 62
36397674 2022
2
Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases. 62
35848586 2022
3
Severe coronavirus disease 2019 in a patient with TAFRO syndrome: A case report. 62
35919675 2022
4
Kaposi's Sarcoma-associated Herpesvirus Replication and Transcription Activator Protein Activates CD274/PD-L1 Gene Promoter. 62
36411531 2022
5
Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease. 62
36414812 2022
6
Unicentric Castleman Disease: A Rare Diagnosis of Radiological and Histological Correlation. 62
36373120 2022
7
Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report. 62
35927344 2022
8
Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy. 62
36401154 2022
9
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. 62
36433996 2022
10
Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine. 62
36298590 2022
11
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis. 62
36175555 2022
12
Multicentric Castleman disease with trismus. 62
36315065 2022
13
Multicentric Castleman Disease: The Hyaline Vascular Type Without HIV Association in a Young Male With Cutaneous Manifestation and Renal Impairment. 62
36407208 2022
14
A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions. 62
36264007 2022
15
Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review. 62
35770616 2022
16
[Castleman disease]. 62
36192235 2022
17
Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease. 62
36142213 2022
18
Idiopathic Multicentric Castleman Disease with Strikingly Elevated IgG4 Concentration in the Serum and Abundant IgG4-Positive Cells in the Tissue: A Case Report. 62
36140662 2022
19
Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report. 62
36143899 2022
20
How we manage idiopathic multicentric Castleman disease. 62
36125948 2022
21
Spontaneous Pulmonary Embolism Leading to Sudden Cardiac Arrest and Perimortem C-Section in a 39-Week Parturient During Induction of Labor: A Case Report. 62
36258925 2022
22
Different Types of Skin Lesions in Multicentric Castleman Disease. 62
35022346 2022
23
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. 62
35793409 2022
24
A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome 62
35699306 2022
25
Case of idiopathic multicentric Castleman's disease: the master mimicker. 62
35961687 2022
26
Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. 62
35997567 2022
27
Immunotherapy for KSHV-associated diseases. 62
35803203 2022
28
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. 62
35507638 2022
29
Recent Advances in IgG4-Related Kidney Disease. 62
35788361 2022
30
[The clinical features of Castleman disease in the head and neck]. 62
35822384 2022
31
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis. 62
35772433 2022
32
Psoas and Mediastinal Abscesses During Intravenous Tocilizumab Treatment in Multicentric Castleman Disease. 62
35732449 2022
33
International definition of iMCD-TAFRO: future perspectives. 62
35474036 2022
34
Severe Inflammatory Idiopathic Multicentric Castleman's Disease Coexisting with Advanced Renal Cancer: A Case Report. 62
35418533 2022
35
Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO. 62
35488725 2022
36
Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease? 62
35249898 2022
37
Historical and pathological overview of Castleman disease. 62
35474035 2022
38
Leucine-rich a-2 glycoprotein as a potential biomarker of idiopathic multicentric Castleman disease with pulmonary involvement: a single-center case-control study from Japan. 62
35693615 2022
39
TAFRO Syndrome: A Disease Requiring Immediate Medical Attention. 62
35598998 2022
40
Extracorporeal cardiopulmonary resuscitation in a woman with twin pregnancy. 62
33739195 2022
41
POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation. 62
35454046 2022
42
The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease. 62
35484648 2022
43
Cutaneous Plasmacytosis and Idiopathic Multicentric Castleman Disease: A Spectrum of Disease? 62
34966045 2022
44
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. 62
35015310 2022
45
Idiopathic multicentric Castleman disease presenting progressive reticular honeycomb infiltration of lung and immunoglobulin G and immunoglobulin G4 dominant hypergammaglobulinemia: a case report. 62
34218552 2022
46
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. 62
35104370 2022
47
Synchronous visceral Kaposi sarcoma and extracavitary primary effusion lymphoma in a patient with AIDS. 62
35351773 2022
48
Glycogen synthase kinase 3β/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO. 62
34873687 2022
49
Case of unilateral pellucid marginal corneal degeneration progressing to corneal perforation with keratoconus in contralateral eye. 62
35128154 2022
50
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. 62
35100929 2022

Variations for Multicentric Castleman Disease

Expression for Multicentric Castleman Disease

Search GEO for disease gene expression data for Multicentric Castleman Disease.

Pathways for Multicentric Castleman Disease

Pathways related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 VEGFA TNFRSF8 SDC1 IRF4 IL6R IL6
2
Show member pathways
13.68 VEGFA SDC1 IL6R IL6 IL10 H2AC18
3
Show member pathways
13.32 TNFRSF8 IL6R IL6 IL10 CD4 CCR6
4
Show member pathways
13.17 VEGFA TNFRSF8 SDC1 IRF4 IL6R IL6
5 12.37 TNFRSF8 PAX5 IRF4 IL10 CD79A CD38
6 12.06 IL10 IL6 IL6R VEGFA
7 11.83 BCL6 IL10 IL6 IL6R IRF4 VEGFA
8 11.79 VEGFA IL6 IL10 CCR6
9 11.77 SDC1 IL6 CD79A CD19
10
Show member pathways
11.69 IL6 CRP CD4
11 11.68 IRF4 IL10 CD4 CCR6
12 11.67 IL6 IL10 CD4
13
Show member pathways
11.64 VEGFA IL6R IL6
14 11.6 CD4 IL6 IL6R IRF4
15 11.59 CD79A CD19 BCL6
16 11.57 IL6R IL6 IL10
17 11.56 SDC1 IL6 IL10 CD79A CD4 CD38
18 11.55 IRF4 IL10 BCL6
19 11.5 VEGFA IL6R IL6
20 11.5 IRF4 IL6 IL10 CD4 CD38 CD19
21 11.48 VEGFA IL6R IL6
22 11.4 IL6R IL6 CRP
23 11.39 VEGFA IL6R IL6 ALK
24 11.17 IL6 IL10 CD4
25 11.13 VEGFA IL6 IL10
26 11.08 PAX5 IRF4 IL6 IL10 CRP CD79A

GO Terms for Multicentric Castleman Disease

Cellular components related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.73 SDC1 IL6R CD79A CD4 CD19 CCR6
2 interleukin-6 receptor complex GO:0005896 8.92 IL6R IL6

Biological processes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.03 VEGFA IL6R IL6 CD4
2 B cell differentiation GO:0030183 9.95 PAX5 IL10 CD79A BCL6
3 liver regeneration GO:0097421 9.93 IL6 IL10 HAMP
4 positive regulation of MAPK cascade GO:0043410 9.92 ALK CD4 IL6 IL6R VEGFA
5 B cell proliferation GO:0042100 9.76 IL10 CD79A CD38 BCL6
6 negative regulation of bone resorption GO:0045779 9.73 IL6 HAMP CD38
7 hepatic immune response GO:0002384 9.67 IL6R IL6
8 acute-phase response GO:0006953 9.56 IL6R IL6 HAMP CRP
9 T-helper 17 cell lineage commitment GO:0072540 9.1 IRF4 IL6R IL6

Sources for Multicentric Castleman Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....